

Na druhou stranu některé klinické studie naznačují, že vliv GLP-1RA a dalších antidiabetik na riziko zlomenin může být heterogenní a závislý na konkrétní molekule i metabolickém kontextu pacienta. Zdá se však, že farmakologická intervence pomocí GLP-1RA představuje z hlediska muskuloskeletálního systému bezpečnější alternativu

k radikálním chirurgickým přístupům, které jsou spojeny s vyšším rizikem fraktur (2).

K objasnění jejich přímých účinků na kostní tkáň a jejich dopadu u rizikových skupin, zejména žen po menopauze, je proto zapotřebí dalších prospektivních a cílených studií.

**PROHLÁŠENÍ AUTORŮ: Prohlášení o původnosti:** Publikace byla zpracována s využitím uvedené literatury a nebyla publikována ani zaslána k recenznímu řízení do jiného média. **Střet zájmů:** Žádný. **Financování:** Ne. **Poděkování:** N/A. **Registrace v databázích:** N/A. **Projednání etickou komisí:** N/A.

## LITERATURA

- Lingvay I, Cohen RV, Roux CWL, et al. Obesity in adults. *Lancet*. 2024 Sep 7;404(10456):972-987. doi: 10.1016/S0140-6736(24)01210-8. Epub 2024 Aug 16. PMID: 39159652.
- Kim MJ, Kim S, Jung HN, et al. Effects of Anti-Obesity Strategies on Bone Mineral Density: A Comprehensive Meta-Analysis of Randomized Controlled Trials. *J Obes Metab Syndr*. 2025 Jan 30;34(1):41-53. doi: 10.7570/jomes24009. Epub 2025 Jan 13. PMID: 39800333; PMCID: PMC11799600.
- Paccou J, Compston JE. Bone health in adults with obesity before and after interventions to promote weight loss. *Lancet Diabetes Endocrinol*. 2024 Oct;12(10):748-760. doi: 10.1016/S2213-8587(24)00163-3. Epub 2024 Jul 22. Erratum in: *Lancet Diabetes Endocrinol*. 2024 Sep;12(9):e18. doi: 10.1016/S2213-8587(24)00235-3. PMID: 39053479.
- Yosibash Z, Trabelsi N, Buchnik I, et al. Hip fracture risk assessment in elderly and diabetic patients: combining autonomous finite element analysis and machine learning. *J Bone mineral research: Off J Am Soc Bone Mineral Res*. (2023) 38:876–86. doi: 10.1002/jbmr.4805
- Martiniakova M, Biro R, Penzes N, et al. Links among obesity, type 2 diabetes mellitus, and osteoporosis: bone as a target. *Int J Mol Sci*. (2024) 25(9):4827. doi: 10.3390/ijms25094827
- Graaf CD, Donnelly D, Wootten D, et al. Glucagon-Like Peptide-1 and Its Class B G Protein-Coupled Receptors: A Long March to Therapeutic Successes. *Pharmacol Rev*. 2016 Oct;68(4):954-1013. doi: 10.1124/pr.115.011395. PMID: 27630114; PMCID: PMC5050443
- Drucker DJ. Mechanisms of Action and Therapeutic Application of Glucagon-like Peptide-1. *Cell Metab*. 2018 Apr 3;27(4):740-756. doi: 10.1016/j.cmet.2018.03.001. PMID: 29617641.
- Wang JY, Wang QW, Yang XY, et al. GLP-1 receptor agonists for the treatment of obesity: Role as a promising approach. *Front Endocrinol (Lausanne)*. 2023 Feb 1;14:1085799. doi: 10.3389/fendo.2023.1085799. PMID: 36843578; PMCID: PMC9945324.
- Mariam Z, Niaz SK. Glucagon-like peptide agonists: A prospective review. *Endocrinol Diabetes Metab*. 2024 Jan;7(1):e462. doi: 10.1002/edm2.462. Epub 2023 Dec 14. PMID: 38093651; PMCID: PMC10782143.
- Viljoen A, Bain SC. Glucagon-Like Peptide 1 Therapy: From Discovery to Type 2 Diabetes and Beyond. *Endocrinol Metab (Seoul)*. 2023 Feb;38(1):25-33. doi: 10.3803/EnM.2022.1642. Epub 2023 Feb 6. PMID: 36740965; PMCID: PMC10008669.
- Blackman A, Foster GD, Zammit G, et al. Tirzepatide for the Treatment of Obstructive Sleep Apnea and Obesity. *N Engl J Med*. 2024;391(7):607-620. doi:10.1056/NEJMoa2404859
- Bettge K, Kahle M, Abd El Aziz MS, et al. Occurrence of nausea, vomiting and diarrhoea reported as adverse events in clinical trials studying glucagon-like peptide-1 receptor agonists: A systematic analysis of published clinical studies. *Diabetes Obes Metab*. 2017;19(3):336-347. doi:10.1111/dom.12824
- Smits MM, Van Raalte DH. Safety of GLP-1 Receptor Agonists: Adverse Effects and Characteristics. *Front Endocrinol (Lausanne)*. 2021;12:651095. doi:10.3389/fendo.2021.651095
- Nauck MA, Quast DR, Wefers J, et al. GLP-1 receptor agonists in the treatment of type 2 diabetes - state-of-the-art. *Mol Metab*. 2021;46:101102. doi:10.1016/j.molmet.2020.101102
- Hammad BF, Zafar N, Ullah M, et al. Exploring the multifaceted roles of GLP-1 receptor agonists: a comprehensive review. *Front Clin Diabetes Healthc*. 2025 Jul 10;6:1590530. doi: 10.3389/fcdhc.2025.1590530. PMID: 40708853; PMCID: PMC12286811.
- Bilgin E, Venerito V, Bogdanos DP. Glucagon-Like Peptide-1 (GLP-1) receptor agonists in rheumatology: A review of current evidence and future directions. *Autoimmun Rev*. 2025 Aug 29;24(9):103864. doi: 10.1016/j.autrev.2025.103864. Epub 2025 Jul 3. PMID: 40617296.
- Marso SP, Daniels GH, Brown-Frandsen K, et al. Liraglutide and Cardiovascular Outcomes in Type 2 Diabetes. *N Engl J Med*. 2016;375(4):311-322. doi:10.1056/NEJMoa1603827
- Davies MJ, Aroda VR, Collins BS, et al. Management of Hyperglycemia in Type 2 Diabetes, 2022. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). *Diabetes Care*. 2022;45(11):2753-2786
- Moiz A, Filion KB, Tsoukas MA, et al. Mechanisms of GLP-1 Receptor Agonist-Induced Weight Loss: A Review of Central and Peripheral Pathways in Appetite and Energy Regulation. *Am J Med*. 2025 Jun;138(6):934-940. doi: 10.1016/j.amjmed.2025.01.021. Epub 2025 Jan 31. PMID: 39892489.
- Svačina S. Agonisté GLP-1 propojují léčbu obezity, diabetu i psoriázy. *Medical Tribune*. 2025, roč. 21, č. 19, s. 4-5. ISSN 1214-8725.
- Wang L, Volkow ND, Kaelber DC, et al. Semaglutide or Tirzepatide and Optic Nerve and Visual Pathway Disorders in Type 2 Diabetes. *JAMA Netw Open*. 2025;8(8):e2526327. doi:10.1001/jamanetworkopen.2025.26327
- Hathaway JT, Shah MP, Hathaway DB, et al. Risk of Nonarteritic Anterior Ischemic Optic Neuropathy in Patients Prescribed Semaglutide. *JAMA Ophthalmol*. 2024 Aug 1;142(8):732-739. doi: 10.1001/jamaophthol.2024.2296. PMID: 38958939; PMCID: PMC11223051.
- Cai TT, Li HQ, Jiang LL, et al. Effects of GLP-1 receptor agonists on bone mineral density in patients with type 2 diabetes mellitus: a 52-week clinical study. *Biomed Res Int*. 2021;2021:3361309. doi: 10.1155/2021/3361309.
- Akyay OZ, Canturk Z, Selek A, et al. The effects of exenatide and insulin glargine treatments on bone turnover markers and bone mineral density in postmenopausal patients with type 2 diabetes mellitus. *Medicine (Baltimore)*. 2023 Sep 29;102(39):e35394. doi: 10.1097/MD.00000000000035394. PMID: 37773814; PMCID: PMC10545322.
- Pereira M, Jayabalan J, Jørgensen CS, et al. Chronic administration of Glucagon-like peptide-1 receptor agonists improves trabecular bone mass and architecture in ovariectomized mice. *Bone*. (2015) 81:459–67. doi: 10.1016/j.bone.2015.08.006
- Chen M, Lyu Y, Zhao J, et al. Use of GLP-1 receptor agonist and risk of osteoporosis among patients with type 2 diabetes: a real-world study. *Front Endocrinol (Lausanne)*. 2025 May 21;16:1586589. doi: 10.3389/fendo.2025.1586589. PMID: 40469447; PMCID: PMC12133453.
- Drucker DJ. The GLP-1 journey: from discovery science to therapeutic impact. *J Clin Invest*. 2024 Jan 16;134(2):e175634. doi: 10.1172/JCI175634. PMID: 38226625; PMCID: PMC10786682.
- Kim JA, Yoo HJ. Exploring the Side Effects of GLP-1 Receptor Agonist: To Ensure Its Optimal Positioning. *Diabetes Metab J*. 2025 Jul;49(4):525-541. doi: 10.4093/dmj.2025.0242. Epub 2025 Jul 1. PMID: 40631457; PMCID: PMC12270588.
- Witham MD, Granic A, Pearson E, et al. Repurposing Drugs for Diabetes Mellitus as Potential Pharmacological Treatments for Sarcopenia - A Narrative Review. *Drugs Aging*. 2023 Aug;40(8):703-719. doi: 10.1007/s40266-023-01042-4. Epub 2023 Jul 24. PMID: 37486575; PMCID: PMC10371965.
- Neeland IJ, Linge J, Birkenfeld AL. Changes in lean body mass with glucagon-like peptide-1-based therapies and mitigation strategies. *Diabetes Obes Metab*. 2024 Sep;26 Suppl 4:16-27. doi: 10.1111/dom.15728. Epub 2024 Jun 27. PMID: 38937282.
- Gatto A, Liu K, Milan N, et al. The Effects of GLP-1 Agonists on Musculoskeletal Health and Orthopedic Care. *Curr Rev Musculoskelet Med*. 2025 Oct;18(10):469-480. doi: 10.1007/s12178-025-09978-3. Epub 2025 May 15. PMID: 40372699; PMCID: PMC12325148.